Post partum haemorrhage
Conditions
Interventions
Placebo group
Tranexamic acid injection group
Sponsors
Okoko Fiafiata
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: Booked parturients at term
Exclusion criteria
Exclusion criteria: Non consenting women. Multiple pregnancy. Vaginal birth after Caesarean section Intrauterine fetal death. History of venous (deep vein thrombosis and/or pulmonary embolism) thrombosis. History of arterial (angina pectoris myocardial infarction, stroke) thrombosis. History of epilepsy or seizure. Any known cardiovascular, renal, or liver disorders Autoimmune disease Sickle cell disease Antepartum haemorrhage Hypertensive disorders of pregnancy Previous history of postpartum haemorrhage Anaemia in pregnancy History of bleeding disorders Co-existing uterine fibroid Allergy to tranexamic acid
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The Primary outcome measure is the estimated blood loss following vaginal delivery and the difference in haematocrit 24 hours after delivery. | — |
Secondary
| Measure | Time frame |
|---|---|
| The Secondary Outcome Measures include primary PPH following vaginal delivery defined as blood loss>500 ml, need for additional doses of tranexamic acid or uterotonics to control bleeding, need for blood transfusion (volume and amount) after vaginal delivery, and adverse effects to tranexamic acid including mild (nausea, vomiting, headache, skin rash) and major (thromboembolism, maternal death) | — |
Countries
Nigeria
Contacts
Public ContactFiafiata Okoko
Resident in Obgyn
Outcome results
None listed